Evgen Pharma PLC (GB:TCF)
LSE:TCF
TCF Stock Chart & Stats
0.20 p
0.00 p(0.00%)
At close: 4:00 PM EST
0.20 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range0.18 p - 0.30 p
Previous CloseN/A
Volume87.69K
Average Volume (3M)1.69M
Market Cap
£4.19M
Enterprise Value2.74M
Total Cash (Recent Filing)£3.50M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Jun 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,148,963,600
10 Day Avg. Volume2,190,584
30 Day Avg. Volume1,685,058
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA lack of reported debt materially reduces fixed financing costs and bankruptcy risk, improving financial flexibility. For a clinical-stage biotech that will need external funding, zero debt lengthens runway options and lowers near-term interest burden for 2-6 month strategic planning.
Focused Nrf2 Lead Program (SFX-01)A clear scientific focus and a defined lead candidate provide strategic clarity for development and partnering. SFX-01’s platform approach targeting Nrf2 can attract collaborators and milestone-driven licensing deals, supporting durable value creation if clinical data progress continues.
Improving Loss And Cash-burn TrendAn improving trajectory in operating losses and cash burn indicates better cost control or program de-risking, which can extend runway and make partnering or financing easier. While still loss-making, consistent improvement reduces near-term funding pressure over the coming months.
Bears Say
Persistent Negative Cash FlowContinual negative operating and free cash flow means the company cannot self-fund development and will need external capital or partnerships. This structural cash burn increases dilution risk, can constrain program timelines, and limits strategic autonomy over the next several quarters.
Small, Inconsistent Revenue BaseAn inconsistent and minimal revenue base provides no reliable internal funding for R&D or operations. For a clinical-stage firm this underscores reliance on licensing or financing, heightening execution risk if partnerships or capital markets access falter across the 2-6 month horizon.
Structurally Loss-making; Negative ROEOngoing net losses and negative returns on equity erode shareholder value and limit ability to raise non-dilutive capital. Persistent negative profitability weakens bargaining power with potential partners and may force dilutive financings or unfavorable deal terms over the medium term.
Evgen Pharma News
TCF FAQ
What was Evgen Pharma PLC’s price range in the past 12 months?
Evgen Pharma PLC lowest share price was 0.17 p and its highest was 0.30 p in the past 12 months.
What is Evgen Pharma PLC’s market cap?
Evgen Pharma PLC’s market cap is £4.19M.
When is Evgen Pharma PLC’s upcoming earnings report date?
Evgen Pharma PLC’s upcoming earnings report date is Jun 10, 2026 which is in 62 days.
How were Evgen Pharma PLC’s earnings last quarter?
Evgen Pharma PLC released its earnings results on Dec 03, 2025. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Evgen Pharma PLC overvalued?
According to Wall Street analysts Evgen Pharma PLC’s price is currently Overvalued.
Does Evgen Pharma PLC pay dividends?
Evgen Pharma PLC does not currently pay dividends.
What is Evgen Pharma PLC’s EPS estimate?
Evgen Pharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evgen Pharma PLC have?
Evgen Pharma PLC has 2,148,963,600 shares outstanding.
What happened to Evgen Pharma PLC’s price movement after its last earnings report?
Evgen Pharma PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.526%.
Which hedge fund is a major shareholder of Evgen Pharma PLC?
Currently, no hedge funds are holding shares in GB:TCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evgen Pharma PLC
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
ValiRx plc
―
Options Prices
Currently, No data available
---